{"id":47490,"date":"2022-08-19T18:02:43","date_gmt":"2022-08-19T16:02:43","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/non-alcoholic-steatohepatitis-treatment-market-analysis-2022-2030-focus-on-cenicriviroc-elafibranor-ocaliva-obeticholic-acid-selonsertib-researchandmarkets-com\/"},"modified":"2022-08-19T18:02:43","modified_gmt":"2022-08-19T16:02:43","slug":"non-alcoholic-steatohepatitis-treatment-market-analysis-2022-2030-focus-on-cenicriviroc-elafibranor-ocaliva-obeticholic-acid-selonsertib-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/non-alcoholic-steatohepatitis-treatment-market-analysis-2022-2030-focus-on-cenicriviroc-elafibranor-ocaliva-obeticholic-acid-selonsertib-researchandmarkets-com\/","title":{"rendered":"Non-Alcoholic Steatohepatitis Treatment Market Analysis 2022-2030: Focus on Cenicriviroc, Elafibranor, Ocaliva (Obeticholic Acid), Selonsertib &#8211; ResearchAndMarkets.com"},"content":{"rendered":"<div>\n<p>DUBLIN&#8211;(BUSINESS WIRE)&#8211;The <a target=\"_blank\" href=\"https:\/\/www.researchandmarkets.com\/reports\/5641133\/non-alcoholic-steatohepatitis-treatment-market?utm_source=BW&amp;utm_medium=PressRelease&amp;utm_code=6mtjst&amp;utm_campaign=1740402+-+Non-Alcoholic+Steatohepatitis+Treatment+Market+Analysis+2022-2030%3A+Focus+on+Cenicriviroc%2C+Elafibranor%2C+Ocaliva+(Obeticholic+Acid)%2C+Selonsertib&amp;utm_exec=chdo54prd\" rel=\"nofollow noopener\" shape=\"rect\">&#8220;Non-Alcoholic Steatohepatitis Treatment Market, by Drug, by Distribution Channel, and by Region &#8211; Size, Share, Outlook, and Opportunity Analysis, 2022 &#8211; 2030&#8221;<\/a> report has been added to <strong>ResearchAndMarkets.com&#8217;s<\/strong> offering.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20220819005301\/en\/1548933\/4\/logo.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20220819005301\/en\/1548933\/21\/logo.jpg\"><\/a><\/p>\n<p>\nThis report provides an in-depth analysis of the global nonalcoholic steatohepatitis treatment market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year\n<\/p>\n<p>\nBy 2050, this is projected at &gt;29 million people &#8211; a 165% increase over the 2000 level. It is to be noted that these projections imply a steady increase in the overall prevalence of diabetes, from 3.99% in 2000 to 7.21% in 2050.\n<\/p>\n<p>\nHowever, diagnosis of the nonalcoholic steatohepatitis can be difficult to capture in an early stage and can take years before patients show any sort of symptoms which is a major factor hampering the nonalcoholic steatohepatitis treatment market.\n<\/p>\n<p>\n<strong>Key features of the study:<\/strong>\n<\/p>\n<ul>\n<li>\nIt elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market\n<\/li>\n<li>\nThis study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players\n<\/li>\n<li>\nIt profiles key players in the global nonalcoholic steatohepatitis treatment market based on the following parameters &#8211; company highlights, products portfolio, key highlights, financial performance, and strategies\n<\/li>\n<li>\nInsights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics\n<\/li>\n<li>\nThe global nonalcoholic steatohepatitis treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts\n<\/li>\n<li>\nStakeholders would have ease in decision-making through various strategy matrices used in analyzing the global nonalcoholic steatohepatitis treatment market\n<\/li>\n<\/ul>\n<p>\n<strong>Company Profiles:<\/strong>\n<\/p>\n<ul>\n<li>\nAstraZeneca Plc.\n<\/li>\n<li>\nCompany Highlights\n<\/li>\n<li>\nProducts Portfolio\n<\/li>\n<li>\nKey Highlights\n<\/li>\n<li>\nFinancial Performance\n<\/li>\n<li>\nStrategies\n<\/li>\n<li>\nConatus Pharmaceuticals\n<\/li>\n<li>\nEnzo Biochem, Inc.\n<\/li>\n<li>\nGENFIT SA\n<\/li>\n<li>\nGalmed Pharmaceuticals Ltd.\n<\/li>\n<li>\nGilead Science\n<\/li>\n<li>\nImmuron Ltd.\n<\/li>\n<li>\nIntercepts Pharmaceuticals\n<\/li>\n<li>\nNovo Nordisk\n<\/li>\n<li>\nRaptor Pharmaceutical Corporation\n<\/li>\n<li>\nTobira Therapeutics, Inc.\n<\/li>\n<\/ul>\n<p>\n<strong>Research Objectives and Assumptions<\/strong>\n<\/p>\n<ul>\n<li>\nResearch Objectives\n<\/li>\n<li>\nAssumptions\n<\/li>\n<li>\nAbbreviations\n<\/li>\n<\/ul>\n<p>\n<strong>Market Purview<\/strong>\n<\/p>\n<ul>\n<li>\nReport Description\n<\/li>\n<li>\nMarket Definition and Scope\n<\/li>\n<li>\nExecutive Summary\n<\/li>\n<li>\nMarket Snapshot, By Drug\n<\/li>\n<li>\nMarket Snapshot, By Distribution Channel\n<\/li>\n<li>\nMarket Snapshot, By Region\n<\/li>\n<li>\nPublisher Opportunity Map\n<\/li>\n<\/ul>\n<p>\n<strong>Market Dynamics, Regulations, and Trends Analysis<\/strong>\n<\/p>\n<ul>\n<li>\nMarket Dynamics\n<\/li>\n<li>\nDrivers\n<\/li>\n<li>\nRestraints\n<\/li>\n<li>\nMarket Opportunities\n<\/li>\n<li>\nImpact Analysis\n<\/li>\n<li>\nMarket Trends\n<\/li>\n<li>\nRecent Developments\n<\/li>\n<li>\nAcquisitions and Partnerships Scenario\n<\/li>\n<li>\nTechnology Overview\n<\/li>\n<li>\nRegulatory Scenario\n<\/li>\n<li>\nPricing Analysis\n<\/li>\n<li>\nPEST Analysis\n<\/li>\n<li>\nPipeline Product Analysis\n<\/li>\n<li>\nEpidemiology Study\n<\/li>\n<\/ul>\n<p>\n<strong>Global Nonalcoholic Steatohepatitis Treatment Market- Impact of Coronavirus (Covid-19) Pandemic<\/strong>\n<\/p>\n<ul>\n<li>\nOverall Impact\n<\/li>\n<li>\nGovernment Initiatives\n<\/li>\n<li>\nCOVID-19 Impact on the market\n<\/li>\n<\/ul>\n<p>\n<strong>Detailed Segmentation:<\/strong>\n<\/p>\n<p>\n<strong>Global Nonalcoholic Steatohepatitis Treatment Market, By Drug:<\/strong>\n<\/p>\n<ul>\n<li>\nCenicriviroc\n<\/li>\n<li>\nElafibranor\n<\/li>\n<li>\nOcaliva (Obeticholic Acid)\n<\/li>\n<li>\nSelonsertib\n<\/li>\n<\/ul>\n<p>\n<strong>Global Nonalcoholic Steatohepatitis Treatment Market, By Distribution Channel:<\/strong>\n<\/p>\n<ul>\n<li>\nHospital Pharmacies\n<\/li>\n<li>\nRetail Pharmacies\n<\/li>\n<li>\nOnline Pharmacies\n<\/li>\n<\/ul>\n<p>\n<strong>Global Nonalcoholic Steatohepatitis Treatment Market, By Region:<\/strong>\n<\/p>\n<ul>\n<li>\nNorth America\n<\/li>\n<li>\nU.S.\n<\/li>\n<li>\nCanada\n<\/li>\n<li>\nLatin America\n<\/li>\n<li>\nBrazil\n<\/li>\n<li>\nMexico\n<\/li>\n<li>\nArgentina\n<\/li>\n<li>\nRest of Latin America\n<\/li>\n<li>\nEurope\n<\/li>\n<li>\nGermany\n<\/li>\n<li>\nU.K.\n<\/li>\n<li>\nFrance\n<\/li>\n<li>\nItaly\n<\/li>\n<li>\nSpain\n<\/li>\n<li>\nRussia\n<\/li>\n<li>\nRest of Europe\n<\/li>\n<li>\nAsia Pacific\n<\/li>\n<li>\nChina\n<\/li>\n<li>\nIndia\n<\/li>\n<li>\nJapan\n<\/li>\n<li>\nAustralia\n<\/li>\n<li>\nSouth Korea\n<\/li>\n<li>\nASEAN\n<\/li>\n<li>\nRest of Asia Pacific\n<\/li>\n<li>\nMiddle East\n<\/li>\n<li>\nGCC\n<\/li>\n<li>\nIsrael\n<\/li>\n<li>\nRest of Middle East\n<\/li>\n<li>\nAfrica\n<\/li>\n<li>\nSouth Africa\n<\/li>\n<li>\nCentral Africa\n<\/li>\n<li>\nNorth Africa\n<\/li>\n<\/ul>\n<p>\nFor more information about this report visit <a target=\"_blank\" href=\"https:\/\/www.researchandmarkets.com\/reports\/5641133\/non-alcoholic-steatohepatitis-treatment-market?utm_source=BW&amp;utm_medium=PressRelease&amp;utm_code=6mtjst&amp;utm_campaign=1740402+-+Non-Alcoholic+Steatohepatitis+Treatment+Market+Analysis+2022-2030%3A+Focus+on+Cenicriviroc%2C+Elafibranor%2C+Ocaliva+(Obeticholic+Acid)%2C+Selonsertib&amp;utm_exec=chdo54prd\" rel=\"nofollow noopener\" shape=\"rect\">https:\/\/www.researchandmarkets.com\/r\/t0uc4y<\/a>\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nResearchAndMarkets.com<br \/>\n<br \/>Laura Wood, Senior Press Manager<br \/>\n<br \/><a target=\"_blank\" href=\"m&#97;&#x69;&#x6c;&#x74;o&#58;&#112;&#x72;&#x65;s&#115;&#64;&#x72;&#x65;se&#97;&#x72;&#x63;&#x68;a&#110;&#x64;&#x6d;&#x61;r&#107;&#101;&#x74;&#x73;&#46;&#99;&#111;&#x6d;\" rel=\"nofollow noopener\" shape=\"rect\">p&#114;&#101;&#x73;&#x73;&#64;r&#101;&#115;&#x65;&#x61;rc&#104;&#97;&#x6e;&#x64;ma&#114;&#x6b;&#x65;&#x74;s&#46;&#99;&#x6f;&#x6d;<\/a>\n<\/p>\n<p>\nFor E.S.T. Office Hours Call 1-917-300-0470<br \/>\n<br \/>For U.S.\/CAN Toll Free Call 1-800-526-8630<br \/>\n<br \/>For GMT Office Hours Call +353-1-416-8900\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;Non-Alcoholic Steatohepatitis Treatment Market, by Drug, by Distribution Channel, and by Region &#8211; Size, Share, Outlook, and Opportunity Analysis, 2022 &#8211; 2030&#8221; report has been added to ResearchAndMarkets.com&#8217;s offering. This report provides an in-depth analysis of the global nonalcoholic steatohepatitis treatment market, and provides market size (US$ Million) and compound annual growth rate &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/non-alcoholic-steatohepatitis-treatment-market-analysis-2022-2030-focus-on-cenicriviroc-elafibranor-ocaliva-obeticholic-acid-selonsertib-researchandmarkets-com\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-47490","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Non-Alcoholic Steatohepatitis Treatment Market Analysis 2022-2030: Focus on Cenicriviroc, Elafibranor, Ocaliva (Obeticholic Acid), Selonsertib - ResearchAndMarkets.com - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/non-alcoholic-steatohepatitis-treatment-market-analysis-2022-2030-focus-on-cenicriviroc-elafibranor-ocaliva-obeticholic-acid-selonsertib-researchandmarkets-com\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Non-Alcoholic Steatohepatitis Treatment Market Analysis 2022-2030: Focus on Cenicriviroc, Elafibranor, Ocaliva (Obeticholic Acid), Selonsertib - ResearchAndMarkets.com - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;Non-Alcoholic Steatohepatitis Treatment Market, by Drug, by Distribution Channel, and by Region &#8211; Size, Share, Outlook, and Opportunity Analysis, 2022 &#8211; 2030&#8221; report has been added to ResearchAndMarkets.com&#8217;s offering. This report provides an in-depth analysis of the global nonalcoholic steatohepatitis treatment market, and provides market size (US$ Million) and compound annual growth rate ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/non-alcoholic-steatohepatitis-treatment-market-analysis-2022-2030-focus-on-cenicriviroc-elafibranor-ocaliva-obeticholic-acid-selonsertib-researchandmarkets-com\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-08-19T16:02:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220819005301\/en\/1548933\/21\/logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/non-alcoholic-steatohepatitis-treatment-market-analysis-2022-2030-focus-on-cenicriviroc-elafibranor-ocaliva-obeticholic-acid-selonsertib-researchandmarkets-com\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/non-alcoholic-steatohepatitis-treatment-market-analysis-2022-2030-focus-on-cenicriviroc-elafibranor-ocaliva-obeticholic-acid-selonsertib-researchandmarkets-com\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Non-Alcoholic Steatohepatitis Treatment Market Analysis 2022-2030: Focus on Cenicriviroc, Elafibranor, Ocaliva (Obeticholic Acid), Selonsertib &#8211; ResearchAndMarkets.com\",\"datePublished\":\"2022-08-19T16:02:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/non-alcoholic-steatohepatitis-treatment-market-analysis-2022-2030-focus-on-cenicriviroc-elafibranor-ocaliva-obeticholic-acid-selonsertib-researchandmarkets-com\\\/\"},\"wordCount\":576,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/non-alcoholic-steatohepatitis-treatment-market-analysis-2022-2030-focus-on-cenicriviroc-elafibranor-ocaliva-obeticholic-acid-selonsertib-researchandmarkets-com\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220819005301\\\/en\\\/1548933\\\/21\\\/logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/non-alcoholic-steatohepatitis-treatment-market-analysis-2022-2030-focus-on-cenicriviroc-elafibranor-ocaliva-obeticholic-acid-selonsertib-researchandmarkets-com\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/non-alcoholic-steatohepatitis-treatment-market-analysis-2022-2030-focus-on-cenicriviroc-elafibranor-ocaliva-obeticholic-acid-selonsertib-researchandmarkets-com\\\/\",\"name\":\"Non-Alcoholic Steatohepatitis Treatment Market Analysis 2022-2030: Focus on Cenicriviroc, Elafibranor, Ocaliva (Obeticholic Acid), Selonsertib - ResearchAndMarkets.com - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/non-alcoholic-steatohepatitis-treatment-market-analysis-2022-2030-focus-on-cenicriviroc-elafibranor-ocaliva-obeticholic-acid-selonsertib-researchandmarkets-com\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/non-alcoholic-steatohepatitis-treatment-market-analysis-2022-2030-focus-on-cenicriviroc-elafibranor-ocaliva-obeticholic-acid-selonsertib-researchandmarkets-com\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220819005301\\\/en\\\/1548933\\\/21\\\/logo.jpg\",\"datePublished\":\"2022-08-19T16:02:43+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/non-alcoholic-steatohepatitis-treatment-market-analysis-2022-2030-focus-on-cenicriviroc-elafibranor-ocaliva-obeticholic-acid-selonsertib-researchandmarkets-com\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/non-alcoholic-steatohepatitis-treatment-market-analysis-2022-2030-focus-on-cenicriviroc-elafibranor-ocaliva-obeticholic-acid-selonsertib-researchandmarkets-com\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/non-alcoholic-steatohepatitis-treatment-market-analysis-2022-2030-focus-on-cenicriviroc-elafibranor-ocaliva-obeticholic-acid-selonsertib-researchandmarkets-com\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220819005301\\\/en\\\/1548933\\\/21\\\/logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220819005301\\\/en\\\/1548933\\\/21\\\/logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/non-alcoholic-steatohepatitis-treatment-market-analysis-2022-2030-focus-on-cenicriviroc-elafibranor-ocaliva-obeticholic-acid-selonsertib-researchandmarkets-com\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Non-Alcoholic Steatohepatitis Treatment Market Analysis 2022-2030: Focus on Cenicriviroc, Elafibranor, Ocaliva (Obeticholic Acid), Selonsertib &#8211; ResearchAndMarkets.com\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Non-Alcoholic Steatohepatitis Treatment Market Analysis 2022-2030: Focus on Cenicriviroc, Elafibranor, Ocaliva (Obeticholic Acid), Selonsertib - ResearchAndMarkets.com - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/non-alcoholic-steatohepatitis-treatment-market-analysis-2022-2030-focus-on-cenicriviroc-elafibranor-ocaliva-obeticholic-acid-selonsertib-researchandmarkets-com\/","og_locale":"en_US","og_type":"article","og_title":"Non-Alcoholic Steatohepatitis Treatment Market Analysis 2022-2030: Focus on Cenicriviroc, Elafibranor, Ocaliva (Obeticholic Acid), Selonsertib - ResearchAndMarkets.com - Pharma Trend","og_description":"DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;Non-Alcoholic Steatohepatitis Treatment Market, by Drug, by Distribution Channel, and by Region &#8211; Size, Share, Outlook, and Opportunity Analysis, 2022 &#8211; 2030&#8221; report has been added to ResearchAndMarkets.com&#8217;s offering. This report provides an in-depth analysis of the global nonalcoholic steatohepatitis treatment market, and provides market size (US$ Million) and compound annual growth rate ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/non-alcoholic-steatohepatitis-treatment-market-analysis-2022-2030-focus-on-cenicriviroc-elafibranor-ocaliva-obeticholic-acid-selonsertib-researchandmarkets-com\/","og_site_name":"Pharma Trend","article_published_time":"2022-08-19T16:02:43+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220819005301\/en\/1548933\/21\/logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/non-alcoholic-steatohepatitis-treatment-market-analysis-2022-2030-focus-on-cenicriviroc-elafibranor-ocaliva-obeticholic-acid-selonsertib-researchandmarkets-com\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/non-alcoholic-steatohepatitis-treatment-market-analysis-2022-2030-focus-on-cenicriviroc-elafibranor-ocaliva-obeticholic-acid-selonsertib-researchandmarkets-com\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Non-Alcoholic Steatohepatitis Treatment Market Analysis 2022-2030: Focus on Cenicriviroc, Elafibranor, Ocaliva (Obeticholic Acid), Selonsertib &#8211; ResearchAndMarkets.com","datePublished":"2022-08-19T16:02:43+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/non-alcoholic-steatohepatitis-treatment-market-analysis-2022-2030-focus-on-cenicriviroc-elafibranor-ocaliva-obeticholic-acid-selonsertib-researchandmarkets-com\/"},"wordCount":576,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/non-alcoholic-steatohepatitis-treatment-market-analysis-2022-2030-focus-on-cenicriviroc-elafibranor-ocaliva-obeticholic-acid-selonsertib-researchandmarkets-com\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220819005301\/en\/1548933\/21\/logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/non-alcoholic-steatohepatitis-treatment-market-analysis-2022-2030-focus-on-cenicriviroc-elafibranor-ocaliva-obeticholic-acid-selonsertib-researchandmarkets-com\/","url":"https:\/\/pharma-trend.com\/en\/non-alcoholic-steatohepatitis-treatment-market-analysis-2022-2030-focus-on-cenicriviroc-elafibranor-ocaliva-obeticholic-acid-selonsertib-researchandmarkets-com\/","name":"Non-Alcoholic Steatohepatitis Treatment Market Analysis 2022-2030: Focus on Cenicriviroc, Elafibranor, Ocaliva (Obeticholic Acid), Selonsertib - ResearchAndMarkets.com - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/non-alcoholic-steatohepatitis-treatment-market-analysis-2022-2030-focus-on-cenicriviroc-elafibranor-ocaliva-obeticholic-acid-selonsertib-researchandmarkets-com\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/non-alcoholic-steatohepatitis-treatment-market-analysis-2022-2030-focus-on-cenicriviroc-elafibranor-ocaliva-obeticholic-acid-selonsertib-researchandmarkets-com\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220819005301\/en\/1548933\/21\/logo.jpg","datePublished":"2022-08-19T16:02:43+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/non-alcoholic-steatohepatitis-treatment-market-analysis-2022-2030-focus-on-cenicriviroc-elafibranor-ocaliva-obeticholic-acid-selonsertib-researchandmarkets-com\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/non-alcoholic-steatohepatitis-treatment-market-analysis-2022-2030-focus-on-cenicriviroc-elafibranor-ocaliva-obeticholic-acid-selonsertib-researchandmarkets-com\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/non-alcoholic-steatohepatitis-treatment-market-analysis-2022-2030-focus-on-cenicriviroc-elafibranor-ocaliva-obeticholic-acid-selonsertib-researchandmarkets-com\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220819005301\/en\/1548933\/21\/logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220819005301\/en\/1548933\/21\/logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/non-alcoholic-steatohepatitis-treatment-market-analysis-2022-2030-focus-on-cenicriviroc-elafibranor-ocaliva-obeticholic-acid-selonsertib-researchandmarkets-com\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Non-Alcoholic Steatohepatitis Treatment Market Analysis 2022-2030: Focus on Cenicriviroc, Elafibranor, Ocaliva (Obeticholic Acid), Selonsertib &#8211; ResearchAndMarkets.com"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/47490","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=47490"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/47490\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=47490"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=47490"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=47490"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}